

Precision Medicine Testing Recommendations For:

General Solid Tumors/Thyroid CA that have mutation specific biomarker indications

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
▪ Treatment eligible ▪ Metastatic or unresectable solid tumor • Advanced or metastatic thyroid cancer who require systemic therapy and are radioactive iodine-refractory	▪ Upon progression ▪ Blood sample ▪ Tissue when available	▪ Preferred: ○ NGS for TMB and MSI testing ▪ Emerging biomarkers: ○ NRG1

BRAF V600E Mutation

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
▪ Treatment eligible ▪ All Stage IV stage solid tumors	▪ At time of initial diagnosis ▪ Recurrence ▪ Tissue or liquid	▪ Preferred: ○ BRAF V600E

HER2 Overexpression

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
▪ Treatment eligible ▪ Early Breast Cancer ▪ Metastatic Breast Cancer ▪ Refractory metastatic cancers – gastric, CRC ▪ Lung HER2 mutation	▪ At time of initial diagnosis ▪ Recurrence ▪ Tissue or liquid	▪ Preferred: ○ HER2 amplification or overexpression ○ HER2 mutation

IDH1 Mutation

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
- Treatment eligible - AML - Cholangiocarcinoma	- At time of initial diagnosis - Recurrence - Tissue or liquid	- Preferred: - IDH1 mutation

NTRK Fusion

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
- Treatment eligible - Metastatic or unresectable solid tumor	- At time of initial diagnosis - Recurrence - Tissue or liquid	- Preferred: - NGS - If unable to get NGS - IHC, FISH and/or PCR

RET

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
- Treatment eligible - RET Mutation - Advanced medullary thyroid cancer - RET Fusion - All Stage IV stage solid tumors	- At time of initial diagnosis - Recurrence - Tissue or liquid	- Preferred: - NGS - Germline RET proto-oncogene - If unable to get NGS - FISH and/or PCR

TMB

Testing Recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
- Treatment eligible - TMB High - All Stage IV stage solid tumors	- At time of initial diagnosis - Recurrence - Tissue or liquid	- Preferred: - NGS

dMMR

Testing recommendations

Who Should Be Tested	When & What Should Be Tested?	What Tests Should Be Considered?
▪ Treatment eligible ▪ MMR deficient ○ All Stage IV stage solid tumors	▪ At time of initial diagnosis ▪ Recurrence ▪ Tissue or liquid	▪ Preferred: ○ IHC